SG11201909963YA - Methods for treating dravet syndrome - Google Patents
Methods for treating dravet syndromeInfo
- Publication number
- SG11201909963YA SG11201909963YA SG11201909963YA SG11201909963YA SG 11201909963Y A SG11201909963Y A SG 11201909963YA SG 11201909963Y A SG11201909963Y A SG 11201909963YA SG 11201909963Y A SG11201909963Y A SG 11201909963YA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- charlottesville
- pct
- methods
- dravet syndrome
- Prior art date
Links
- 201000007547 Dravet syndrome Diseases 0.000 title abstract 3
- 208000036572 Myoclonic epilepsy Diseases 0.000 title abstract 3
- 206010073677 Severe myoclonic epilepsy of infancy Diseases 0.000 title abstract 3
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 229940127291 Calcium channel antagonist Drugs 0.000 abstract 1
- 239000000480 calcium channel blocker Substances 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Inorganic Chemistry (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762490357P | 2017-04-26 | 2017-04-26 | |
| PCT/US2018/029610 WO2018200844A1 (en) | 2017-04-26 | 2018-04-26 | Methods for treating dravet syndrome |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201909963YA true SG11201909963YA (en) | 2019-11-28 |
Family
ID=63920144
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10202111892XA SG10202111892XA (en) | 2017-04-26 | 2018-04-26 | Methods for treating dravet syndrome |
| SG11201909963Y SG11201909963YA (en) | 2017-04-26 | 2018-04-26 | Methods for treating dravet syndrome |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10202111892XA SG10202111892XA (en) | 2017-04-26 | 2018-04-26 | Methods for treating dravet syndrome |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20200163943A1 (ru) |
| EP (1) | EP3615010B1 (ru) |
| JP (1) | JP7326159B2 (ru) |
| KR (1) | KR102616994B1 (ru) |
| CN (1) | CN110799215A (ru) |
| AU (1) | AU2018260693B2 (ru) |
| CA (1) | CA3061712A1 (ru) |
| IL (1) | IL270137B2 (ru) |
| RU (1) | RU2767661C2 (ru) |
| SG (2) | SG10202111892XA (ru) |
| WO (1) | WO2018200844A1 (ru) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017070680A1 (en) | 2015-10-22 | 2017-04-27 | Cavion Llc | Methods for treating angelman syndrome and related disorders |
| US11602512B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11504347B1 (en) | 2016-07-22 | 2022-11-22 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| UY37341A (es) | 2016-07-22 | 2017-11-30 | Flamel Ireland Ltd | Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada |
| US11986451B1 (en) | 2016-07-22 | 2024-05-21 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11602513B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12186296B1 (en) | 2016-07-22 | 2025-01-07 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12478604B1 (en) | 2016-07-22 | 2025-11-25 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| EP3585376A4 (en) | 2017-02-15 | 2020-11-25 | Cavion, Inc. | CALCIUM CHANNELS INHIBITORS |
| NZ758559A (en) | 2017-04-26 | 2025-08-29 | Cavion Inc | Methods for improving memory and cognition and for treating memory and cognitive disorders |
| CA3115235A1 (en) | 2018-10-03 | 2020-04-09 | Cavion, Inc. | Treating essential tremor using (r)-2-(4-isopropylphenyl)-n-(1-(5-(2,2,2-trifluoroethoxy)pyridin-2-yl)ethyl)acetamide |
| WO2020178695A1 (en) | 2019-03-01 | 2020-09-10 | Flamel Ireland Limited | Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state |
| CN112353767A (zh) * | 2020-11-16 | 2021-02-12 | 海南锦瑞制药有限公司 | 一种盐酸地尔硫卓和普瑞巴林组合物及其制备方法及其应用 |
| KR20230121776A (ko) * | 2020-12-16 | 2023-08-21 | 캄테크, 인크. | 아마니타 무스카리아 화합물 |
| GB202101462D0 (en) * | 2021-02-03 | 2021-03-17 | Sanchez Hector Mario | Combination therapy for treating executive function disorders |
| BR112023024354A2 (pt) * | 2021-05-24 | 2024-02-06 | Cavion Inc | Método de tratamento de tremor essencial |
| KR20240046879A (ko) | 2021-08-17 | 2024-04-11 | 한국과학기술원 | Cav3.1 유전자를 표적으로 하는 안티센스 올리고뉴클레오타이드 및 그의 용도 |
| IT202100023651A1 (it) * | 2021-09-14 | 2023-03-14 | Edilio Lancellotti | Niaprazina per uso veterinario nel trattamento di disturbi del sistema nervoso centrale |
| US11583510B1 (en) | 2022-02-07 | 2023-02-21 | Flamel Ireland Limited | Methods of administering gamma hydroxybutyrate formulations after a high-fat meal |
| US11779557B1 (en) | 2022-02-07 | 2023-10-10 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| WO2025022402A1 (en) * | 2023-07-25 | 2025-01-30 | Ariel Scientific Innovations Ltd. | Compositions and methods for treating behavior diseases |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101466676B (zh) * | 2006-04-12 | 2012-07-18 | 默沙东公司 | 吡啶基酰胺类t-型钙通道拮抗剂 |
| US8377968B2 (en) * | 2008-06-02 | 2013-02-19 | Zalicus Pharmaceuticals, Ltd. | N-piperidinyl acetamide derivatives as calcium channel blockers |
| JP5846372B2 (ja) * | 2010-01-29 | 2016-01-20 | 国立大学法人 岡山大学 | Ｄｒａｖｅｔ症候群の発症可能性の判定方法およびその利用 |
| WO2012094615A2 (en) * | 2011-01-07 | 2012-07-12 | Zenyaku Kogyo Kabushikikaisha | Use of cav3.1 selective t-type calcium channel antagonists |
| GB2539472A (en) * | 2015-06-17 | 2016-12-21 | Gw Res Ltd | Use of cannabinoids in the treatment of epilepsy |
| US9351968B1 (en) * | 2015-09-09 | 2016-05-31 | Ovid Therapeutics Inc | Methods of treating developmental disorders using pipradrol |
| WO2017070680A1 (en) * | 2015-10-22 | 2017-04-27 | Cavion Llc | Methods for treating angelman syndrome and related disorders |
-
2018
- 2018-04-26 EP EP18791035.1A patent/EP3615010B1/en active Active
- 2018-04-26 SG SG10202111892XA patent/SG10202111892XA/en unknown
- 2018-04-26 AU AU2018260693A patent/AU2018260693B2/en active Active
- 2018-04-26 SG SG11201909963Y patent/SG11201909963YA/en unknown
- 2018-04-26 WO PCT/US2018/029610 patent/WO2018200844A1/en not_active Ceased
- 2018-04-26 CA CA3061712A patent/CA3061712A1/en active Pending
- 2018-04-26 KR KR1020197034824A patent/KR102616994B1/ko active Active
- 2018-04-26 CN CN201880040389.9A patent/CN110799215A/zh active Pending
- 2018-04-26 JP JP2019558464A patent/JP7326159B2/ja active Active
- 2018-04-26 IL IL270137A patent/IL270137B2/en unknown
- 2018-04-26 RU RU2019137951A patent/RU2767661C2/ru active
- 2018-04-26 US US16/608,355 patent/US20200163943A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| RU2019137951A (ru) | 2021-05-26 |
| JP7326159B2 (ja) | 2023-08-15 |
| US20200163943A1 (en) | 2020-05-28 |
| EP3615010A1 (en) | 2020-03-04 |
| IL270137B2 (en) | 2024-04-01 |
| IL270137B1 (en) | 2023-12-01 |
| RU2019137951A3 (ru) | 2021-08-20 |
| EP3615010A4 (en) | 2021-06-30 |
| AU2018260693A1 (en) | 2019-11-14 |
| RU2767661C2 (ru) | 2022-03-18 |
| JP2020517708A (ja) | 2020-06-18 |
| WO2018200844A1 (en) | 2018-11-01 |
| CA3061712A1 (en) | 2018-11-01 |
| KR20190139302A (ko) | 2019-12-17 |
| KR102616994B1 (ko) | 2023-12-26 |
| CN110799215A (zh) | 2020-02-14 |
| AU2018260693B2 (en) | 2024-01-11 |
| SG10202111892XA (en) | 2021-12-30 |
| IL270137A (ru) | 2019-12-31 |
| EP3615010B1 (en) | 2024-08-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201909963YA (en) | Methods for treating dravet syndrome | |
| SG11201909960UA (en) | Methods for improving memory and cognition and for treating memory and cognitive disorders | |
| SG11201908971RA (en) | Erbb-2 and erbb3 binding bispecific antibodies for use in the treatment f cells that have an nrg1 fusion gene | |
| SG11201906431UA (en) | Method for the treatment of thromboembolism | |
| SG11201807660QA (en) | Cyclic di-nucleotide compounds and methods of use | |
| SG11201804901WA (en) | Compounds for the treatment of cancer and inflammatory disease | |
| SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
| SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
| SG11201808222RA (en) | Methods of treatment of cholestatic diseases | |
| SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
| SG11201901597UA (en) | Macrophage stimulating protein receptor (or ron - recepteur d' origine nantais) antibodies and uses thereof | |
| SG11201903076QA (en) | Carbamoyl phenylalaninol compounds and uses therof | |
| SG11201808676RA (en) | Methods of treating pediatric cancers | |
| SG11201907701YA (en) | Composition and method for preventing or delaying onset of myopia comprising atropine | |
| SG11201805385QA (en) | Bromodomain and extra-terminal protein inhibitor combination therapy | |
| SG11201909837YA (en) | Methods for treating lung disorders | |
| SG11201809882XA (en) | Pharmaceutical combinations for treating cancer | |
| SG11201804587QA (en) | Isoindole compounds | |
| SG11201900043TA (en) | Antibody formulations | |
| SG11201809031XA (en) | Acetyl-leucine or a pharmaceutically acceptable salt thereof for improved mobility and cognitive function | |
| SG11201907153RA (en) | Topical formulations and methods | |
| SG11201907844TA (en) | Novel spiro and cyclic bis-benzylidine proteasome inhibitor for the treatment of cancer, diabetes and neurological disorders | |
| SG11201901689YA (en) | Compounds for treating diseases associated with a mitochondrial dysfonction | |
| SG11201901048VA (en) | Pharmaceutical compositions and uses directed to lysosomal storage disorders | |
| SG11201906666QA (en) | Methods of preparing cytotoxic benzodiazepine derivatives |